日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Targeting AXL can effectively overcome c-Met-induced therapeutic resistance in renal cancer and promote tumor cell death through increased oxidative stress

靶向AXL可有效克服c-Met诱导的肾癌治疗耐药性,并通过增加氧化应激促进肿瘤细胞死亡。

Akash Sabarwal ,Marc Machaalani ,Laxminarayan Rawat ,Johannes Wedel ,Saba Tabasum ,Yuzuru Sasamoto ,Florian Buerger ,Josie Ascione ,Marc Eid ,Karl Semaan ,Eddy Saad ,Yifan Yang ,Dongwon Lee ,F Stephen Hodi ,Matthew L Freedman ,Gwo-Shu Mary Lee ,Murugabaskar Balan ,Toni K Choueiri ,Soumitro Pal

A novel combination therapy with Cabozantinib and Honokiol effectively inhibits c-Met-Nrf2-induced renal tumor growth through increased oxidative stress

卡博替尼和和厚朴酚的新型联合疗法通过增加氧化应激有效抑制 c-Met-Nrf2 诱导的肾肿瘤生长

Laxminarayan Rawat, Murugabaskar Balan, Yuzuru Sasamoto, Akash Sabarwal, Soumitro Pal

A Combination therapy using an mTOR inhibitor and Honokiol effectively induces autophagy through the modulation of AXL and Rubicon in renal cancer cells and restricts renal tumor growth following organ transplantation

使用 mTOR 抑制剂和和厚朴酚的联合疗法可通过调节肾癌细胞中的 AXL 和 Rubicon 有效诱导自噬,并限制器官移植后的肾肿瘤生长

Akash Sabarwal, Johannes Wedel, Kaifeng Liu, David Zurakowski, Samik Chakraborty, Evelyn Flynn, David M Briscoe, Murugabaskar Balan, Soumitro Pal